首页 | 本学科首页   官方微博 | 高级检索  
     


Successful treatment with rituximab of an infant with refractory autoimmune hemolytic anemia
Authors:Kunihiko Moriya  Tetsuro Matsuhashi  Masaei Onuma  Hidetaka Niizuma  Takeshi Rikiishi  Hiroshi Asada  Jun Suzuki  Yoji Sasahara  Shigeo Kure
Affiliation:1. Department of Pediatrics, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan
2. Department of Pediatrics, Iwaki Kyoritsu Hospital, 16 Kuzehara, Uchigomimaya-machi, Iwaki, Fukushima, 973-8555, Japan
Abstract:Autoimmune hemolytic anemia (AIHA) is a rare disease in infants, for which steroids are recognized as a first-line therapy for patients. Rituximab, a humanized monoclonal antibody raised against CD20, has been used in the treatment of autoimmune diseases, including AIHA, in adults and children. Due to limited follow-up study of the use of rituximab in the treatment for AIHA, its long-term efficacy, adverse effects, and immunological reconstitution of B cells have not been fully evaluated in infants. Here, we report a 3-month-old female patient with refractory AIHA, who was successfully treated with rituximab. Hemolytic anemia improved rapidly, and there were no severe adverse effects caused by rituximab. After 4.5 months following rituximab treatment, peripheral B cells were gradually reconstituted and required no intravenous immunoglobulin replacement thereafter. The patient has remained disease-free for more than 30 months without any additional treatment. This case suggests that rituximab may be a valuable therapeutic option, given its efficacy and minimal adverse effects in infants with therapy-resistant AIHA.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号